# Neuronetics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Neuronetics, Inc.). ## Overview Neuronetics, Inc. develops and commercializes NeuroStar Advanced Therapy System, a non-invasive medical device used in psychiatric care, along with recurring treatment-session access codes and related services. The company is based in the United States and sells primarily to psychiatrists and psychiatric practices, with a small international distribution footprint. ## Products & services • NeuroStar Advanced Therapy System • Treatment session access codes • SenStar treatment links • Clinic-based treatment services • Service, repair, and extended warranty contracts - **NeuroStar system sales and rentals** (9%) — Capital equipment sales, rentals, upgrades, and related hardware for the NeuroStar platform. - **Treatment sessions** (30%) — Recurring access codes and treatment-session revenue used with the NeuroStar system. - **Clinic revenue** (60%) — Revenue from treatments performed in company-operated or affiliated clinic settings. - **Other revenue** (1%) — Service, repair, research collaboration, and extended warranty revenue. - NeuroStar Advanced Therapy System - Treatment session access codes - SenStar treatment links - Clinic-based treatment services - Service, repair, and extended warranty contracts ## Customers Neuronetics sells to psychiatrists, group psychiatric practices, and treatment centers that use NeuroStar to treat patients with major depressive disorder. Its revenue also depends on third-party payors, including Medicare, managed care plans, and commercial insurers, because patient reimbursement supports treatment adoption and utilization. - **Psychiatrists and psychiatric practices** (primary) — Buy NeuroStar systems and treatment-session access to treat MDD patients in-office and generate recurring patient revenue. - **Clinic operators** (primary) — Operate treatment sites and earn clinic revenue from performed sessions and patient fees. - **Third-party payors** (primary) — Medicare, managed care, and commercial insurers reimburse treatments and influence utilization. - **International distributors** (secondary) — Purchase and distribute products in select non-U.S. markets. - Psychiatrists buying systems to offer in-office treatment - Group psychiatric practices expanding treatment capacity - Clinic operators generating reimbursed patient-fee revenue - Patients whose treatment is reimbursed by payors - Third-party payors that determine reimbursement economics ## Geography The business is overwhelmingly U.S.-centric, with the United States accounting for 98% of revenue in the nine months ended September 30, 2025. International sales are limited and are handled through independent distributors in a few select markets outside the U.S. - **United States** (98%) — Nine months ended September 30, 2025 - **International** (2%) — Nine months ended September 30, 2025 - United States is the core market and main revenue source - International sales are small and distributor-based - Clinic revenue is tied to treatment activity in 15 U.S. states - Manufacturing components are outsourced, with final handling in Pennsylvania - U.S. reimbursement dynamics are central to demand ## Strategy Neuronetics is focused on expanding adoption of NeuroStar through direct sales coverage, customer support, and clinical evidence that supports additional indications. It also emphasizes growing recurring revenue from treatment sessions and clinic operations, while relying on outsourced manufacturing and distributor channels for parts of its operating model. - **Expand installed base and utilization** (short-term) — More systems in the field and higher session volume increase recurring revenue opportunities. - **Develop additional indications** (medium-term) — Broader clinical use can expand the addressable market and support adoption. - **Scale clinic revenue** (medium-term) — Clinic operations add a direct patient-fee stream and deepen market penetration. - Expand direct sales coverage across psychiatrists and practices - Increase recurring treatment-session revenue per installed system - Grow clinic revenue through treatment-center utilization - Advance hardware, software, and clinical development - Use outsourced manufacturing to support the device platform ## Risks Neuronetics depends on reimbursement, physician adoption, and patient willingness to pursue treatment, so demand can be sensitive to payor policy and macro conditions. The company also faces execution risk from outsourced manufacturing, product concentration around NeuroStar, and financial covenant/liquidity pressure associated with its capital structure. - **Reimbursement and payor policy risk** [high] — Clinic and treatment-session demand depend on Medicare, managed care, and commercial coverage. - **Macroeconomic demand sensitivity** [medium] — Patients may delay or forego medical services during weaker economic conditions. - **Manufacturing and supply chain risk** [high] — Components are produced by third-party contract manufacturers and assembled through outsourced partners. - **Product concentration risk** [high] — The business is centered on NeuroStar and related treatment-session revenue. - **Liquidity and covenant risk** [high] — Borrowings under the Perceptive Facility include revenue and liquidity covenants. - Reimbursement changes can affect patient access and treatment economics - Demand is sensitive to physician adoption and patient willingness to pay - Outsourced manufacturing creates supply and quality execution risk - Revenue is concentrated in one core platform and related sessions - Debt covenants and liquidity needs can constrain flexibility ## Accounting Revenue recognition is judgmental because clinic revenue uses an expected-value approach for net patient fees, including contractual allowances and discounts. The company also has multiple revenue streams with different timing profiles, including capital equipment sales, recurring treatment-session access codes, and service or warranty contracts, which can create quarter-to-quarter mix changes and estimation risk. - **Clinic revenue estimation** — Can materially affect reported revenue and receivables - **Variable consideration** — Creates estimation uncertainty in clinic revenue - **Multiple revenue streams** — Affects revenue mix and comparability across periods - **Warranty and service contracts** — Influences deferred revenue and service-cost estimates - Clinic revenue depends on estimates of net patient fees - Variable consideration affects transaction price and timing - System sales, sessions, and clinic revenue have different margins - Service and warranty revenue may be deferred over contract terms - Outsourced manufacturing affects inventory and cost estimates --- *Last updated: 2026-04-29T04:41:20.287475+00:00*